Filing Flows › Gossamer Bio (GOSS) › R&D spending
Gossamer Bio (GOSS) R&D spending by quarter
Gossamer Bio's R&D spending was $26.4M in Q2 2026 (second quarter 2026), -39% from Q1 2026. Over the last 7 quarters it ranged from $26.4M (Q2 2026) to $48.9M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $26.4M | -39% | -36% |
| Q1 2026 | $43.1M | -12% | +13% |
| Q4 2025 | $48.9M | +7% | +36% |
| Q3 2025 | $45.5M | +10% | — |
| Q2 2025 | $41.6M | +9% | — |
| Q1 2025 | $38.0M | +5% | — |
| Q4 2024 | $36.1M | — | — |
Q2 2026 at a glance
Gossamer Bio, Q2 2026: revenue $9.2M (-20% year over year), operating margin -282.2%, net earnings $16.9M, operating cash flow −$39.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Gossamer Bio's R&D spending?
Gossamer Bio's R&D spending was $26.4M in Q2 2026 (second quarter 2026), -39% from Q1 2026.
How has Gossamer Bio's R&D spending changed?
Over the last 7 quarters it ranged from $26.4M (Q2 2026) to $48.9M (Q4 2025).